Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

346.12 -6.51 (-1.85%)

Streaming Delayed Price Updated: 11:04 AM EDT, May 29, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	45,612
Open	352.63
Bid (Size)	344.13 (40)
Ask (Size)	346.16 (40)
Prev. Close	352.63
Today's Range	343.86 - 355.00
52wk Range	35.21 - 366.52
Shares Outstanding	44,712,538
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗

May 26, 2026

Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases.

Via The Motley Fool

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗

May 21, 2026

Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.

Via The Motley Fool

Performance

YTD	+20.9%	+20.9%
1 Month	+7.5%	+7.5%
3 Month	+1.7%	+1.7%
6 Month	+76.2%	+76.2%
1 Year	+834.7%	+834.7%

More News

Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗

May 21, 2026

Via The Motley Fool

Praxis Precision Medicines (NASDAQ:PRAX) Beats Q1 Estimates as FDA Accepts Two Key Drug Applications ↗

May 07, 2026

Via Chartmill

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗

May 17, 2026

Via The Motley Fool

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗

May 17, 2026

Via The Motley Fool

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗

May 17, 2026

Via The Motley Fool

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗

May 17, 2026

Via The Motley Fool

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗

May 17, 2026

Via The Motley Fool

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗

May 17, 2026

Via The Motley Fool

Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗

May 17, 2026

Via The Motley Fool

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗

May 16, 2026

Via The Motley Fool

Praxis (PRAX) Q1 2026 Earnings Call Transcript ↗

May 12, 2026

Via The Motley Fool

Praxis Precision Medicines Q1 Earnings Call Highlights ↗

May 08, 2026

Via MarketBeat

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 07, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 05, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

May 04, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

April 14, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026

April 13, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

April 06, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 02, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs

March 30, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗

March 22, 2026

Via The Motley Fool

Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗

March 18, 2026

Via The Motley Fool

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗

March 16, 2026

Via The Motley Fool

Frequently Asked Questions

Is Praxis Precision Medicines, Inc. - Common Stock publicly traded?

Yes, Praxis Precision Medicines, Inc. - Common Stock is publicly traded.

What exchange does Praxis Precision Medicines, Inc. - Common Stock trade on?

Praxis Precision Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Praxis Precision Medicines, Inc. - Common Stock?

The ticker symbol for Praxis Precision Medicines, Inc. - Common Stock is PRAX on the Nasdaq Stock Market

What is the current price of Praxis Precision Medicines, Inc. - Common Stock?

The current price of Praxis Precision Medicines, Inc. - Common Stock is 346.12

When was Praxis Precision Medicines, Inc. - Common Stock last traded?

The last trade of Praxis Precision Medicines, Inc. - Common Stock was at 05/29/26 11:04 AM ET

What is the market capitalization of Praxis Precision Medicines, Inc. - Common Stock?

The market capitalization of Praxis Precision Medicines, Inc. - Common Stock is 15.48B

How many shares of Praxis Precision Medicines, Inc. - Common Stock are outstanding?

Praxis Precision Medicines, Inc. - Common Stock has 15B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.